<div id="readability-page-1">Monument Capital Management increased its position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 109.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 12,566 shares of the company's stock after acquiring an additional 6,554 shares during the period. Monument Capital Management's holdings in Johnson &amp; Johnson were worth $2,330,000 at the end of the most recent quarter.<div>Get Johnson &amp; Johnson alerts:</div><ul><li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li></ul>Other large investors also recently made changes to their positions in the company. Evolution Wealth Management Inc. bought a new stake in Johnson &amp; Johnson during the second quarter worth approximately $27,000. Semmax Financial Advisors Inc. boosted its stake in shares of Johnson &amp; Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after acquiring an additional 72 shares in the last quarter. GFG Capital LLC acquired a new position in shares of Johnson &amp; Johnson in the 2nd quarter worth $35,000. 1248 Management LLC acquired a new stake in shares of Johnson &amp; Johnson during the first quarter worth $48,000. Finally, Vermillion &amp; White Wealth Management Group LLC lifted its holdings in shares of Johnson &amp; Johnson by 66.4% during the second quarter. Vermillion &amp; White Wealth Management Group LLC now owns 376 shares of the company's stock valued at $57,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 69.55% of the company's stock. <h2>Analysts Set New Price Targets</h2>Several analysts have issued reports on the company. Johnson Rice set a $190.00 price objective on Johnson &amp; Johnson and gave the stock a &#34;hold&#34; rating in a report on Wednesday, October 22nd. Barclays lifted their target price on shares of Johnson &amp; Johnson from $176.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, September 13th. Daiwa Capital Markets upgraded shares of Johnson &amp; Johnson from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $203.00 price objective on the stock in a research report on Monday, October 20th. Finally, Guggenheim increased their target price on Johnson &amp; Johnson from $206.00 to $227.00 and gave the company a &#34;buy&#34; rating in a report on Friday, December 5th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $210.25.<ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul>View Our Latest Research Report on Johnson &amp; Johnson<h2>More Johnson &amp; Johnson News</h2>Here are the key news stories impacting Johnson &amp; Johnson this week:<ul> <li>Positive Sentiment: EU approval for Tremfya in pediatric plaque psoriasis expands JNJ’s commercial opportunity in immunology and makes Tremfya the first IL‑23 inhibitor cleared for any pediatric indication — a potential revenue tailwind. JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis</li> <li>Positive Sentiment: FDA cleared a subcutaneous formulation of Rybrevant for NSCLC, improving patient convenience and potentially broadening uptake versus IV; this strengthens oncology growth prospects. J&amp;J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)</li> <li>Positive Sentiment: Multiple analyst pieces and model portfolios continue to flag JNJ as a high‑yield, defensive stock for 2026 — supporting demand from income and conservative equity investors. Top 5 High-Yield S&amp;P 500 Stocks to Buy for Reliable Returns in 2026</li> <li>Neutral Sentiment: Stifel Nicolaus reiterated a Hold rating on JNJ — a reminder that some analysts remain cautious on near‑term upside despite pipeline progress. Stifel Nicolaus Reaffirms Their Hold Rating on Johnson &amp; Johnson (JNJ)</li> <li>Neutral Sentiment: Market commentary and earnings previews highlight stronger Q3 results and recent rally/valuation debates — these narratives help explain interest in the stock but don’t change fundamentals immediately. Here’s Why Johnson &amp; Johnson (JNJ) Surged in Q3</li> <li>Negative Sentiment: A Baltimore jury ordered J&amp;J to pay roughly $1.5B in a talc/asbestos mesothelioma case — the largest single‑plaintiff talc award reported — creating legal liability risk, potential settlement/appeal costs, and headline volatility. J&amp;J vows appeal after US jury hits it with record $1.5 billion talc cancer award</li> <li>Negative Sentiment: Company statements and multiple outlets report the verdict and ongoing exposure (tens of thousands of talc suits), which could weigh on sentiment, raise legal reserves or influence long‑term liability assumptions. Over $1.5 Billion Baltimore Verdict Holds Johnson &amp; Johnson Liable Over Iconic Baby Powder</li> </ul><h2>Johnson &amp; Johnson Stock Up 1.1%</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul>JNJ stock opened at $208.01 on Thursday. The company has a 50 day moving average of $199.06 and a two-hundred day moving average of $180.31. The company has a market cap of $501.14 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 2.23 and a beta of 0.36. Johnson &amp; Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion for the quarter. On average, equities analysts anticipate that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year. <h2>Johnson &amp; Johnson Announces Dividend</h2>The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson &amp; Johnson's dividend payout ratio (DPR) is 50.19%. <h2>Johnson &amp; Johnson Company Profile</h2> (Free Report)Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world. The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.<h2>Further Reading</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul>Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).<img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>Before you consider Johnson &amp; Johnson, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

Monument Capital Management increased its stake in Johnson & Johnson by 109% in Q3, now holding 12,566 shares valued at $2.33 million. This move is part of broader investment activities by various firms in J&J. Analysts have mixed ratings on J&J, with a consensus target price of $210.25. Recent positive developments include EU approval for Tremfya and FDA clearance for Rybrevant, while legal challenges persist with a $1.5 billion talc case verdict.

Johnson & Johnson $JNJ Shares Acquired by Monument Capital Management